Items where Author is "Aballéa, Samuel"

Group by: Item Type | No Grouping
Number of items: 3.
Kragh, Nana, Tytula, Anna, Pochopien, Michał, Aballéa, Samuel, Toumi, Mondher, Hakimi, Zalmai, Nazir, Jameel, Bystrická, Linda and Fatoye, Francis
ORCID: https://orcid.org/0000-0002-3502-3953
(2023)
Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK.
European Journal of Haematology, 110 (3).
pp. 262-270.
ISSN 0902-4441
Mancuso, Maria Elisa
ORCID: https://orcid.org/0000-0002-7113-4028, Castaman, Giancarlo
ORCID: https://orcid.org/0000-0003-4973-1317, Pochopien, Michal, Aballéa, Samuel, Drzewiecka, Aleksandra
ORCID: https://orcid.org/0000-0003-3396-8571, Hakimi, Zalmai
ORCID: https://orcid.org/0000-0001-5835-8599, Nazir, Jameel and Fatoye, Francis
ORCID: https://orcid.org/0000-0002-3502-3953
(2022)
Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe.
Journal of Medical Economics, 25 (1).
pp. 1068-1075.
ISSN 1369-6998
Pasi, John ORCID: https://orcid.org/0000-0003-3394-2099, Hermans, Cédric
ORCID: https://orcid.org/0000-0001-5429-8437, Hakimi, Zalmai, Nazir, Jameel, Aballéa, Samuel, Ezzalfani, Monia and Fatoye, Francis
ORCID: https://orcid.org/0000-0002-3502-3953
(2022)
Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study.
Therapeutic Advances in Hematology, 13.
pp. 1-9.
ISSN 2040-6207